ClinicalTrials.gg
Sign In
RecruitingNCT07321977MyokinesisUpdated Nov 3, 2026

Assessment of a Portable Digital Device for Quantified Analysis of Markerless Walking in Volunteers With Neuromuscular Diseases or Asymptomatic Volunteers

An interventional study of Gait analysis via video capture in Spinal Muscular Atrophy (SMA), Charcot-Marie-Tooth and Muscular Dystrophy, sponsored by Institut de Myologie, France. Recruiting at 1 site in France. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Institut de Myologie, France · Not applicable, Interventional, and Other

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 3, 2026Primary completion movedStudy completion movedGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

In recent years, knowledge of neuromuscular diseases has advanced considerably, and new therapeutic avenues are beginning to emerge. The proliferation of clinical trials has created a need to identify biomarkers that are both sensitive to changes and specific to the disease. Current gait tests only consider the time factor and not the evolution of the patient's biomechanics, which may prove insufficient for patients whose symptoms generally progress slowly. Quantifying gait parameters in neuromuscular patients therefore appears necessary. This is why we propose to study markerless gait analysis in this population, which would allow for simple and effective monitoring of kinematic parameters without resorting to complex equipment incompatible with routine clinical practice.

02

Conditions studied

  • Spinal Muscular Atrophy (SMA)
  • Charcot-Marie-Tooth
  • Muscular Dystrophy
  • Myotonic Dystrophy

Keywords

  • gait analysis
  • neuromuscular
  • disease
  • markerless
03

In context

Muscular Atrophy, Spinal

282 studies on the registry are indexed under Muscular Atrophy, Spinal; 73 are open to participants now.

This study's planned enrollment of 30 is close to the median of 29 across 156 interventional studies indexed under Muscular Atrophy, Spinal.

Browse Muscular Atrophy, Spinal studies →

Lead sponsor

Institut de Myologie, France is the lead sponsor of 30 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

  • All volunteers

    • Age between 18 and 65
    • Ambulatory
    • to participate in the study
    • Member of or beneficiary of a social security system

  • Volunteers with a neuromuscular disease

    • Confirmed diagnosis of a neuromuscular disease of genetic origin (medical document to be provided upon enrollment in the study with proof of diagnosis) belonging to the list above.
    • Ability to walk for 2 minutes without assistance.
    • Ability to stand up from a chair with armrests at least 3 times in 30 seconds.
    • Ability to climb an inclined plane independently or with assistance to access the movement analysis room.

Exclusion Criteria

  • All volunteers

    • Individuals under guardianship, curatorship, or legal protection
    • Pregnant or breastfeeding women
    • Non-ambulatory individuals
    • Individuals with epilepsy
    • Skin conditions preventing the placement of VICON motion sensors

  • Asymptomatic volunteers

    • Unstable respiratory or cardiac problems
    • Neurological, musculoskeletal, or psychiatric problems

  • Volunteers with a neuromuscular disease

    • Recent trauma or serious falls (≤ 6 months)
    • Individuals who have fallen more than twice in the past year and at least once in the past three months
    • Use of assistive devices such as rigid knee braces or walkers
    • Unstable cardiomyopathy
    • Individuals awaiting diagnosis

Exclusion criteria

  • Inability to comply with the protocol requirements
  • Medical or social conditions that could interfere with the study, as determined by the coordinating investigator or co-investigators.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Other
    Volunteers with Neuromuscular disease or asymptomatic

    All participants have the same intervention. The intervention is to walk with shoes in a gait analysis room with VICON markers on the body. At the same time, the participant will be film by two smartphones to compare the kinematics and the spatio-temporal parameters between a marker-based and a markerless gait analysis.

    Other: Gait analysis via video capture

Interventions

  • OtherGait analysis via video capture

    Using motion analysis software integrated into a smartphone

06

What researchers measure

Primary outcomes

  1. Vicon vs Myokinesis system correlation coefficient

    Correlation coefficient between measurements from the two systems in both groups, for spatiotemporal parameters and joint range of motion in the sagittal plane at the hip, knee, and ankle

    Time frame: Day 1

07

Study locations

1 of 1 sites recruiting
  • Centre d'Exploration et d'Évaluation Neuromusculaire
    Paris, France
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.

Of 48 non-industry interventional studies with no phase under Muscular Atrophy, Spinal, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 9 months is below that.

Counting every sponsor, half of 57 studies reached it within 27 months; a quarter within 17 and three quarters within 51.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Jul 2026 → Dec 2026 and completion Jan 2027 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2025
First posted
Jan 7, 2026
StartActual
Mar 3, 2026
Primary completionEst.
Dec 31, 2026was Jul 2026
CompletionEst.
Dec 31, 2026was Jan 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 6, 2026→Dec 31, 2026
Nov 3, 2026
Study completion
Jan 6, 2027→Dec 31, 2026
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Primary completion Jul 6, 2026→Dec 31, 2026
    Study completion Jan 6, 2027→Dec 31, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07321977
Lead sponsor
Institut de Myologie, France
Responsible party
Sponsor
First posted
Jan 7, 2026
Start date
Mar 3, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 3, 2026

Study contacts

Pauline SANTMARTY, MsC
Contact
p.santmarty@institut-myologie.org
+33 01 42 16 58 79
Romain FEIGEAN, PhD
Contact
r.feigean@institut-myologie.org
+33 142166649

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Muscular Atrophy, Spinal →

Other studies from this sponsor

Institut de Myologie, France

Start the discussion